Categories
Breast Cancer

Stratifying patients with breast cancer by a 7-gene assay for endocrine therapy [Video]

Current strategies to identify patients with breast cancer who will benefit from radiotherapy or endocrine therapy have been ineffective, with various trials such as the RTOG 9804 trial (NCT00003857) have failed to elucidate the relevant subgroup of patients. Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, describes the benefit of a 7-gene predictive ductal carcinoma in situ (DCIS) biosignature in discerning patients receiving breast conserving surgery (BCS) for DCIS who will benefit adjuvant endocrine therapy. The assay revealed that patients who had an elevated or residual risk were more likely to benefit from radiotherapy and endocrine therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Cord blood transplantation vs MMUD with PTCy in AML [Video]

Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses the finding of a study comparing cord blood transplantation versus mismatched unrelated donor (MMUD) with post-transplant cyclophosphamide (PTCy) in patients with acute myeloid leukemia (AML). The study found that there was a higher rate of non-relapse mortality (NRM) and graft failure in cord blood transplant recipients compared to MMUD recipients. In addition, the study found that the risk of graft-versus-host disease (GvHD) was lower in MMUD recipients treated with PTCy. Overall, this study strongly supports the use of MMUD transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Challenges in CAR-T therapy for myeloid malignancies [Video]

Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses some of the key obstacles to developing CAR-T therapies for myeloid malignancies. To being with, the most commonly expressed antigens in acute myeloid leukemia (AML) are also expressed on normal hematopoietic stem cells (HSCs), which can lead to off-target effects with CAR-T therapy. In addition, patients with myeloid malignancies have a poor immune microenvironment and have often received prior allogeneic transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Exciting CAR-T data in multiple myeloma and follicular lymphoma: CARTITUDE-2, ELARA & ZUMA-5 [Video]

Dholaria Bhagirathbhai, MBBS, Vanderbilt University Medical Center, Nashville, TN, shares his thoughts on the most exciting data in CAR-T therapy that will be released at this year’s Tandem Meetings, including results from the CARTITUDE-2 (NCT04133636), ELARA (NCT03568461), and ZUMA-5 (NCT03105336) studies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Long-term outcomes of AML transplant survivors [Video]

Vivek Patel, MD, Vanderbilt University Medical Center, Nashville, TN, gives an overview of the findings of a study investigating the long-term outcomes of patients with acute myeloid leukemia (AML) who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT), outlining emerging strategies to optimize transplantation outcomes in these patients. Overall, the study found that patients who were relapse-free two years post-transplant had a 10-year overall survival (OS) of 76% and that reduced intensity conditioning (RIC) regimens were associated with a worse OS and leukemia-free survival (LFS). In addition, the probability of death at 10 years in these patients was significantly higher when compared to a matched healthy population. Over the past few years, new strategies including post-transplant cyclophosphamide (PTCy)-based haploidentical stem cell transplantation have greatly improved transplantation outcomes. It is now important to perform an even longer follow-up of these patients to explore the late causes of death in transplant survivors. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.